| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Drs. Wolfe, Nations, Bryan, and Barohn, and L. Herbelin) and Academic Computing Services (Dr. Foster), University of Texas Southwestern Medical Center, Dallas, TX.Presented in part at the 50th annual meeting of the American Academy of Neurology; Minneapolis, MN; April 28, 1998.
Address correspondence and reprint requests to Dr. Gil I. Wolfe, Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-8897.
The authors have developed an MG activities of daily living (ADL) profile (MG-ADL)—a simple eight-question survey of MG symptoms. In 254 consecutive encounters with established MG patients, the authors compared scores from the MG-ADL to the quantitative MG score (QMG)—a standardized, reliable scale used in clinical trials. The mean MG-ADL score was 4.89 ± 3.63. The mean QMG score was 10.80 ± 5.70. Pearson’s correlation coefficient was 0.583 (p < 0.001). The MG-ADL is an easy-to-administer survey of MG that correlates well with the QMG and can serve as a secondary efficacy measurement in clinical trials.
This article has been cited by other articles:
|
|
 |
|
  The Muscle Study Group A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis Neurology, August 5, 2008; 71(6): 394 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Sanders, I. K. Hart, R. Mantegazza, S. S. Shukla, Z. A. Siddiqi, M.H.V. De Baets, A. Melms, M. W. Nicolle, N. Solomons, and D. P. Richman An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis Neurology, August 5, 2008; 71(6): 400 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cossins, G. Burke, S. Maxwell, H. Spearman, S. Man, J. Kuks, A. Vincent, J. Palace, C. Fuhrer, and D. Beeson Diverse molecular mechanisms involved in AChR deficiency due to rapsyn mutations Brain, October 1, 2006; 129(10): 2773 - 2783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Matsumoto, H. Matsuo, H. Sakuma, I.-K. Park, Y. Tsukada, K. Kohyama, T. Kondo, S. Kotorii, and N. Shibuya CDR3 Spectratyping Analysis of the TCR Repertoire in Myasthenia Gravis. J. Immunol., April 15, 2006; 176(8): 5100 - 5107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rowin, M. N. Meriggioli, E. Tuzun, S. Leurgans, and P. Christadoss Etanercept treatment in corticosteroid-dependent myasthenia gravis Neurology, December 28, 2004; 63(12): 2390 - 2392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takamori, M. Motomura, N. Kawaguchi, Y. Nemoto, T. Hattori, H. Yoshikawa, and K. Otsuka Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis Neurology, May 25, 2004; 62(10): 1894 - 1896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ciafaloni, J.M. Massey, B. Tucker-Lipscomb, and D.B. Sanders Mycophenolate mofetil for myasthenia gravis: An open-label pilot study Neurology, January 9, 2001; 56(1): 97 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Romi, G. O. Skeie, J. A. Aarli, and N. E. Gilhus The Severity of Myasthenia Gravis Correlates With the Serum Concentration of Titin and Ryanodine Receptor Antibodies Arch Neurol, November 1, 2000; 57(11): 1596 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jaretzki III, R. J. Barohn, R. M. Ernstoff, H. J. Kaminski, J. C. Keesey, A. S. Penn, and D. B. Sanders Myasthenia gravis: Recommendations for clinical research standards Neurology, July 12, 2000; 55(1): 16 - 23. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jaretzki III, R. J. Barohn, R. M. Ernstoff, H. J. Kaminski, J. C. Keesey, A. S. Penn, and D. B. Sanders Myasthenia gravis: recommendations for clinical research standards Ann. Thorac. Surg., July 1, 2000; 70(1): 327 - 334. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
